drugset / Trial / NCT07059377

Semaglutide for Smoking Cessation in Patients With Diabetes

NCT07059377

Phase 3 Recruiting 100 enrolled Ottawa Heart Institute Research Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

Timeline

Start
2026-02-13
Primary completion
2026-07
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 0.5 mg
Subject Semaglutide Peptide 2 mg
Background Nicotine Unknown